Dabigatran etexilate is an inactive pro-drug that is converted to dabigatran, the active form, by esterase-catalyzed hydrolysis in the plasma and liver. Dabigatran, the main active principle in plasma, is a rapid-acting competitive and reversible direct inhibitor of thrombin. Thrombin, a serine protease, enables thrombus formation by activating factors V, VIII, and XI and catalyzing the conversion of fibrinogen to fibrin. Inhibition of thrombin disrupts the coagulation cascade and inhibits the formation of clots. Unlike heparin, which can only bind free thrombin, dabigatran is capable of inhibiting free thrombin, fibrin-bound thrombin and thrombin-induced platelet aggregation.
Storage conditions: stor in light-resistant and well closed container. protect from moisture below 30 C.
Packaging: : polyethylene nylon plastic bag